K E Sherman

Summary

Affiliation: University of Cincinnati
Country: USA

Publications

  1. pmc Low-level HIV infection of hepatocytes
    Ling Kong
    Division of Digestive Diseases, University of Cincinnati College of Medicine, and Cincinnati Children s Hospital Medical Center, ML 0595, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    Virol J 9:157. 2012
  2. pmc Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach
    Kenneth E Sherman
    University of Cincinnati College of Medicine UC Health, Division of Digestive Diseases, 231 Albert Sabin Way, Cincinnati, OH 45267 0595, USA
    Clin Infect Dis 55:1236-41. 2012
  3. pmc Human immunodeficiency virus and liver disease forum 2010: conference proceedings
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    Hepatology 54:2245-53. 2011
  4. ncbi request reprint Implications of peginterferon use in special populations infected with HCV
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0595, USA
    Semin Liver Dis 23:47-52. 2003
  5. ncbi request reprint New paradigms in the management of hepatitis C virus co-infections
    Kenneth E Sherman
    University of Cincinnati School of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0595, USA
    Nat Clin Pract Gastroenterol Hepatol 4:S10-6. 2007
  6. pmc Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)
    Kenneth E Sherman
    Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA
    J Acquir Immune Defic Syndr 55:597-605. 2010
  7. ncbi request reprint Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients
    Kenneth E Sherman
    Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Gastroenterology 128:313-27. 2005
  8. doi request reprint Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof
    Kenneth E Sherman
    University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA
    Ann N Y Acad Sci 1194:136-40. 2010
  9. ncbi request reprint Health values of patients with chronic hepatitis C infection
    Kenneth E Sherman
    Hepatology and Liver Transplant Medicine Section, Division of Digestive Diseases, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0595, USA
    Arch Intern Med 164:2377-82. 2004
  10. ncbi request reprint Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease
    K E Sherman
    Department of Medicine, University of Cincinnati Medical Center and the Cincinnati VA Medical Center, Cincinnati, OH, USA
    Hepatology 30:265-70. 1999

Research Grants

  1. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth Sherman; Fiscal Year: 2007
  2. Mentorship in Liver Disease
    Kenneth Sherman; Fiscal Year: 2007
  3. Liver Disease and HIV
    Kenneth Sherman; Fiscal Year: 2006
  4. HCV Genomic Variability in HIV Infected Hemophiliacs
    Kenneth Sherman; Fiscal Year: 2004
  5. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth E Sherman; Fiscal Year: 2010

Detail Information

Publications78

  1. pmc Low-level HIV infection of hepatocytes
    Ling Kong
    Division of Digestive Diseases, University of Cincinnati College of Medicine, and Cincinnati Children s Hospital Medical Center, ML 0595, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    Virol J 9:157. 2012
    ..There are only limited data on whether HIV infection occurs within the liver; therefore, we explored early and late stages of the HIV life cycle in two hepatocyte cell lines--Huh7.5 and Huh7.5JFH1--as well as in primary human hepatocytes...
  2. pmc Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach
    Kenneth E Sherman
    University of Cincinnati College of Medicine UC Health, Division of Digestive Diseases, 231 Albert Sabin Way, Cincinnati, OH 45267 0595, USA
    Clin Infect Dis 55:1236-41. 2012
    ..Management of common adverse events including anemia and rash must be embraced by the healthcare provider...
  3. pmc Human immunodeficiency virus and liver disease forum 2010: conference proceedings
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    Hepatology 54:2245-53. 2011
    ....
  4. ncbi request reprint Implications of peginterferon use in special populations infected with HCV
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0595, USA
    Semin Liver Dis 23:47-52. 2003
    ..Use of peginterferons with ribavirin improves response rates in these groups, but does not fully ameliorate the response deficit relative to patients enrolled in typical drug registration clinical trials...
  5. ncbi request reprint New paradigms in the management of hepatitis C virus co-infections
    Kenneth E Sherman
    University of Cincinnati School of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0595, USA
    Nat Clin Pract Gastroenterol Hepatol 4:S10-6. 2007
    ..Treatment must be individualized and attention must be paid to the potential for drug-drug interactions...
  6. pmc Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)
    Kenneth E Sherman
    Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA
    J Acquir Immune Defic Syndr 55:597-605. 2010
    ..A multicenter randomized clinical trial designed to assess the efficacy/safety of pegylated interferon maintenance therapy was performed by the National Institutes of Health-funded AIDS Clinical Trials Group network...
  7. ncbi request reprint Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients
    Kenneth E Sherman
    Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Gastroenterology 128:313-27. 2005
    ..HCV-monoinfected patients. Reasons for this remain unclear. This study evaluated kinetic parameters and treatment responses in co-infected vs monoinfected patients...
  8. doi request reprint Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof
    Kenneth E Sherman
    University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA
    Ann N Y Acad Sci 1194:136-40. 2010
    ..Therefore, the promise of TA-1 adjunctive therapy for HCV remains, but the proof will require investment in large randomized clinical trials of appropriate patient populations...
  9. ncbi request reprint Health values of patients with chronic hepatitis C infection
    Kenneth E Sherman
    Hepatology and Liver Transplant Medicine Section, Division of Digestive Diseases, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0595, USA
    Arch Intern Med 164:2377-82. 2004
    ..Patients with hepatitis C virus (HCV) infection report a reduction in health status, but it is not known how they value their state of health. We assessed health utilities directly from patients with HCV infection...
  10. ncbi request reprint Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease
    K E Sherman
    Department of Medicine, University of Cincinnati Medical Center and the Cincinnati VA Medical Center, Cincinnati, OH, USA
    Hepatology 30:265-70. 1999
    ..Quasispecies complexity was not associated with viral titer, complementary DNA concentration, or genotype. The differences in quasispecies complexity may help explain reports of poor interferon responsiveness in alcoholic patients...
  11. ncbi request reprint Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir
    Kenneth E Sherman
    Div of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    Clin Infect Dis 41:1186-95. 2005
    ..Previous studies have included highly variable antiretroviral regimens. We compared effects of 2 protease inhibitor-based regimens on alanine aminotransferase (ALT) levels and HCV loads in HCV-HIV-coinfected patients initiating HAART...
  12. ncbi request reprint Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus
    Kenneth E Sherman
    Department of Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Clin Infect Dis 35:482-7. 2002
    ..Clinicians should note that test variability precludes direct comparability of HCV RNA titers, particularly in coinfected patients with high titers...
  13. pmc HIV and liver disease forum: conference proceedings
    Kenneth E Sherman
    Division of Digestive Diseases, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA
    Hepatology 45:1566-77. 2007
  14. ncbi request reprint Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    Hepatology 46:2014-20. 2007
  15. ncbi request reprint Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group
    Kenneth E Sherman
    Hepatology and Liver Transplant Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA
    Clin Infect Dis 34:831-7. 2002
    ..5%. Genotype 1 was found in 83.3% of infected patients. Median HCV RNA level was 6.08x106 IU/mL. High virus loads and genotype 1 prevalence may be important to interferon-based antiviral response rates among coinfected patients...
  16. ncbi request reprint Treatment of hepatitis C virus and human immunodeficiency virus co-infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    Clin Gastroenterol Hepatol 3:S118-21. 2005
    ..Human immunodeficiency virus control can be maintained during and after therapy for hepatitis C virus. Important adverse-event profiles associated with drug interactions between didanosine and ribavirin have been described...
  17. pmc Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens
    Kenneth E Sherman
    University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0595, USA
    J Infect Dis 201:712-9. 2010
    ..Interferon-based therapy response rates have been disappointingly low. Baseline HCV complexity and the relationship between complexity and viral kinetic parameters has not been well described in HCV/HIV-coinfected subjects...
  18. pmc Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals
    C M Martin
    Department of Internal Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Viral Hepat 17:588-97. 2010
    ..Several of these O-HBV mutations likely contribute to the lack of detectable HBsAg in O-HBV infection by interfering with detection in serologic assays, altering antigen secretion and/or decreasing replicative fitness...
  19. ncbi request reprint Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis
    N J Shire
    Division of Digestive Diseases, University of Cincinnati, Cincinnati, OH 45267, USA
    J Viral Hepat 14:239-48. 2007
    ..Improved treatments are needed in coinfected patients, especially with genotype 1/4 and high viral load...
  20. ncbi request reprint HCV and HIV: a tale of two viruses
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Rev Gastroenterol Disord 4:S48-54. 2004
    ..However, response rates are lower than those observed in patients with HCV monoinfection. Sustained virologic response rates of 27% to 40% are reported...
  21. pmc Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study
    N Kemmer
    University of Cincinnati, OH, USA
    J Viral Hepat 19:792-800. 2012
    ..There was a significant decline in HRQOL during the initial 12 weeks of therapy. Thereafter, the HRQOL profile differed for subjects with EVR vs without EVR. Maintenance therapy with PEG-IFN had no impact on the HRQOL...
  22. ncbi request reprint Occult hepatitis B in HIV-infected patients
    Norah J Shire
    University of Cincinnati College of Medicine, OH 45267, USA
    J Acquir Immune Defic Syndr 36:869-75. 2004
    ..Though viral titers and serum ALT levels were low, screening of this subset of HIV-infected patients may have implications in terms of antiretroviral therapy and risk of immune reconstitution-associated flares...
  23. pmc Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro
    C M Martin
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Viral Hepat 19:716-23. 2012
    ....
  24. pmc T-helper cells and liver fibrosis in hepatitis C virus-monoinfected patients
    S Rashkin
    Department of Internal Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    J Viral Hepat 17:222-6. 2010
    ..CD4 counts declined during PegIFN treatment, but returned to baseline after completion. The significance of these findings in terms of disease progression and treatment response requires further evaluation...
  25. doi request reprint Response-guided telaprevir combination treatment for hepatitis C virus infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    N Engl J Med 365:1014-24. 2011
    ..We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations...
  26. pmc Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients
    C S Coffin
    Department of Medicine, University of California San Francisco, San Francisco, CA, USA
    Am J Transplant 10:1268-75. 2010
    ..Combination HBIG and antivirals is effective as prophylaxis with no clinical evidence of HBV recurrence but low-level HBV DNA is detectable in approximately 50% of recipients...
  27. ncbi request reprint Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future
    Norah J Shire
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Clin Infect Dis 41:S63-8. 2005
    ..Future therapies, some of which are currently in development, will likely include new targets, such as helicase and polymerase. It is hoped that, as more-effective agents are discovered, the disparity in treatment response will diminish...
  28. pmc The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin
    A A Butt
    Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA
    Aliment Pharmacol Ther 33:1234-44. 2011
    ..The association of anaemia with outcomes in the HCV/HIV coinfected persons undergoing HCV treatment remains unclear...
  29. doi request reprint Viral pathogens
    M V Ragni
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213 4306, USA
    Haemophilia 16:40-6. 2010
    ..The purpose of this chapter is to provide an update on three clinically significant transfusion-transmitted viral pathogens...
  30. ncbi request reprint Prevalence and genotypic variability of TTV in HIV-infected patients
    K E Sherman
    Department of Medicine, University of Cincinnati College of Medicine, Ohio 45267, USA
    Dig Dis Sci 46:2401-7. 2001
    ..Mixed genotypes were more common in those with HIV. Therefore, TTV prevalence, ALT levels, and genomic heterogeneity of TTV all seem to be altered in patients with HIV...
  31. pmc HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?
    J T Blackard
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Viral Hepat 15:323-30. 2008
    ..A comprehensive understanding of virus-virus and virus-cell interactions is critical to the development of novel treatment strategies to combat HCV/HIV co-infection...
  32. ncbi request reprint Diagnosis and management of the HCV/HIV-coinfected patient
    Kenneth E Sherman
    Hepatology and Liver Transplantation Section, University of Cincinnati College of Medicine, Ohio, USA
    AIDS Clin Care 14:39-43, 48. 2002
  33. ncbi request reprint Treatment of hepatitis C virus/HIV coinfection
    Sooyun Chun
    Division of Digestive Diseases, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0595, USA
    Clin Liver Dis 9:525-33, ix. 2005
    ..This article reviews treatment options for patients who are coinfected with HIV and HCV...
  34. ncbi request reprint HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV
    Hongxing Qin
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Blood 105:533-41. 2005
    ..Evolution patterns differ for progressors and nonprogressors. Further understanding of these mechanisms may help identify factors related to progression rate and treatment response...
  35. ncbi request reprint Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine
    M Bessesen
    Department of Medicine, University of Colorado Health Sciences Center, Denver, USA
    Clin Infect Dis 28:1032-5. 1999
    ..Clinicians caring for patients with coinfection with HIV and HBV should be aware of the possibility that a hepatitis B flare may occur in previously asymptomatic carrier patients...
  36. pmc Mechanism of indinavir-induced hyperbilirubinemia
    S D Zucker
    Division of Digestive Diseases and Division of Infectious Diseases, University of Cincinnati, Cincinnati, OH 45267, USA
    Proc Natl Acad Sci U S A 98:12671-6. 2001
    ..Taken together, these findings indicate that elevations in serum-unconjugated bilirubin associated with indinavir treatment result from direct inhibition of bilirubin-conjugating activity...
  37. pmc Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay
    M T Shata
    Internal Medicine, Division of Digestive Diseases, University of Cincinnati, Cincinnati, OH 45267 0595, USA
    J Immunol Methods 328:152-61. 2007
    ..73, p=0.02). Moreover, fine specificities of HEV-specific T cell responses could be identified using overlapping HEV ORF2 peptides...
  38. ncbi request reprint The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients
    Norah J Shire
    Division of Digestive Diseases, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    J Acquir Immune Defic Syndr 44:309-14. 2007
    ..Prevalence estimates vary widely. We determined the prevalence of occult HBV at the University of Cincinnati Infectious Diseases Center (IDC)...
  39. ncbi request reprint Hepatitis C virus coinfection and superinfection
    Jason T Blackard
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Infect Dis 195:519-24. 2007
    ....
  40. pmc Hepatitis E virus antibodies in patients with chronic liver disease
    Muslim Atiq
    University of Cincinnati, Cincinnati, OH 45267, USA
    Emerg Infect Dis 15:479-81. 2009
    ..Our data indicate that HEV seropositivity is high in patients with chronic liver disease and that HEV seroprevalence increases significantly with age...
  41. pmc Genotypic characterization of symptomatic hepatitis E virus (HEV) infections in Egypt
    Jason T Blackard
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    J Clin Virol 46:140-4. 2009
    ..In Egypt, HEV seroprevalence is among the highest in the world; however, only a very limited number of Egyptian HEV sequences are currently available...
  42. pmc HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women
    Jason T Blackard
    Division of Digestive Disease, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Clin Infect Dis 52:674-80. 2011
    ..FIB-4 represents a noninvasive, composite index that is a validated measure of hepatic fibrosis, which is an important indicator of liver disease. To date, there are limited data regarding hepatic fibrosis in women...
  43. ncbi request reprint HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia
    Norah J Shire
    The University of Cincinnati Division of Digestive Diseases, Cincinnati, OH, USA
    Hepatology 44:1146-57. 2006
    ..04). In conclusion, low pretreatment quasispecies complexity may predict peg-IFN response; early peg-IFN response is critical for sustained HCV clearance and is altered in coinfection. Further studies are warranted...
  44. ncbi request reprint Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis
    Norah J Shire
    College of Medicine, University of Cincinnati, 231 Albert Sabin Way, ML 0595, Cincinnati, OH 45267, USA
    Vaccine 24:272-9. 2006
    ..The overall response rate to HAV vaccine in HIV-infected patients is lower than typically cited. Up to 1/2 of HIV-infected patients may be nonresponders. Future research will be required to better understand the correlates of response...
  45. pmc Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one?
    Joseph M Mrus
    Health Services Research and Development, Cincinnati Veterans Affairs Medical Center, Cincinnati, Ohio, USA
    Med Care 44:158-66. 2006
    ....
  46. ncbi request reprint Intrafamilial transmission of hepatitis C virus in patients with hepatitis C and human immunodeficiency virus coinfection
    Daniela R Keiserman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0595, USA
    Am J Gastroenterol 98:878-83. 2003
    ..The aim of this study was to determine whether hepatitis C virus (HCV)/HIV coinfection of index cases increases intrafamilial transmission (sexual and nonsexual contacts) of HCV...
  47. ncbi request reprint Management of HBV/HIV-coinfected Patients
    Norah J Shire
    University of Cincinnati, Division of Digestive Diseases, Cincinnati, Ohio 452670595, USA
    Semin Liver Dis 25:48-57. 2005
    ..All of these agents have been shown to be relatively effective in HBV-monoinfected patients. However, few randomized, controlled HBV treatment trials have been conducted in coinfected subjects, and thus additional studies are warranted...
  48. pmc Variability of the polymerase gene (NS5B) in hepatitis C virus-infected women
    Jason T Blackard
    Department of Internal Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA
    J Clin Microbiol 48:4256-9. 2010
    ..Moreover, differences between NS5B nonsynonymous (dN) and synonymous (dS) mutation rates (dN - dS) were positively correlated with CD4 cell count, while nonsynonymous mutations were strongly correlated with reduced replication in vivo...
  49. ncbi request reprint Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer
    Stephen D Zucker
    Division of Digestive Diseases, University of Cincinnati, Cincinnati, OH 45267 0595, USA
    Hepatology 40:827-35. 2004
    ....
  50. ncbi request reprint Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences
    Jason T Blackard
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Hepatology 44:15-22. 2006
    ....
  51. ncbi request reprint Review article: current status of liver transplantation in HIV-infected patients
    G W Neff
    Division of Digestive Diseases, University of Cincinnati, OH, USA
    Aliment Pharmacol Ther 20:993-1000. 2004
    ..This review will discuss the current clinical status of liver transplantation in individuals suffering from human immunodeficiency virus infection...
  52. pmc Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women
    Peter D Dryer
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    J Antimicrob Chemother 64:945-8. 2009
    ..In the current study, we assessed NS5B resistance mutations in treatment-naive individuals from a prospective natural history study of viral infections in women...
  53. ncbi request reprint Management of hepatitis B virus in HIV-positive patients
    N J Shire
    Division of Digestive Diseases, The University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
    Minerva Gastroenterol Dietol 52:67-87. 2006
    ..Although liver transplant is not commonly undertaken in HIV-positive patients, centers undertaking transplantation report improved survival and low rates of HBV recurrence...
  54. pmc Acute hepatitis C virus infection: a chronic problem
    Jason T Blackard
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Hepatology 47:321-31. 2008
  55. ncbi request reprint Liver biopsy in cirrhotic patients
    Kenneth E Sherman
    University of Cincinnati College of Medicine, Division of Digestive Diseases, Cincinnati, Ohio 45267 0595, USA
    Am J Gastroenterol 102:789-93. 2007
    ..No specific safety issues attributable to a particular biopsy method were identified...
  56. ncbi request reprint Complexity and diversity of hepatitis C virus RNA in african americans and whites: analysis of the envelope-coding domain
    Erica D Keenan
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267 0595, USA
    J Infect Dis 190:511-4. 2004
    ..Racial differences in amino acid usage at otherwise conserved positions were observed. Differences in amino acid representation at key positions are suggestive of immunologic and functional selection along racial lines...
  57. ncbi request reprint Anti-Clq antibodies in patients with chronic hepatitis C infection
    D W Lienesch
    Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Clin Exp Rheumatol 24:183-5. 2006
    ..In this study, we investigate the prevalence of anti-Clq antibody in a population of patients with chronic HCV infection...
  58. ncbi request reprint Diseases of the hepatopulmonary axis
    C A Meyer
    Departments of Radiology and Medicine, University of Cincinnati, 234 Goodman St, ML 0742, Cincinnati, OH 45219 2316, USA
    Radiographics 20:687-98. 2000
    ..Knowledge of these associations will assist the radiologist in forming a meaningful differential diagnosis and may influence treatment decisions...
  59. ncbi request reprint Clinical application of polymerase chain reaction to diagnose Clostridium difficile in hospitalized patients with diarrhea
    Michael S Morelli
    Division of Digestive Diseases, University of Cincinnati, Ohio, USA
    Clin Gastroenterol Hepatol 2:669-74. 2004
    ..We sought to show the usefulness and potential cost effectiveness of polymerase chain reaction (PCR) amplification of toxin B gene for diagnosis of C. difficile-induced diarrhea...
  60. pmc Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals
    Christina M Martin
    Department of Internal Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, OH 45267, USA
    Cytokine 47:194-8. 2009
    ....
  61. ncbi request reprint Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kappaB activation
    Elizabeth A Mann
    Department of Internal Medicine, Division of Digestive Diseases, University of Cincinnati, 231 Albert B Sabin Way, OH 55267 0595, USA
    Virus Res 121:51-7. 2006
    ..Further studies are needed to assess potential associations between specific amino acid substitutions at positions 9-11 and liver disease progression and/or response to treatment in individual patients...
  62. ncbi request reprint The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification
    Jamie C Mandac
    Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    Hepatology 43:661-72. 2006
    ..In this review we discuss the clinical and pathophysiological aspects of IIT, and we are proposing a new, etiology-based classification of IIT, as well as an algorithm for diagnosis and treatment of IIT...
  63. ncbi request reprint Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy
    Jason T Blackard
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Infect Dis 189:1472-81. 2004
    ..These data suggest that there are several mechanisms by which suppression of HIV replication and a reconstituted immune system influence diversity of HCV in HIV-HCV-coinfected subjects...
  64. ncbi request reprint Nucleoside analogues and mitochondrial toxicity
    Russell Fleischer
    Division of Antiviral Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA
    Clin Infect Dis 38:e79-80. 2004
    ..In response, the US product labels for didanosine and ribavirin have been revised to caution clinicians against coadministration of these drugs...
  65. ncbi request reprint Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV
    Camilla S Graham
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02115, USA
    Hepatology 40:125-32. 2004
    ..In conclusion, subjects with coinfection have an alteration of intrahepatic HCV-specific IL-10 cytokine response that may have implications for HCV-related disease progression...
  66. ncbi request reprint End-stage liver disease in persons with hemophilia and transfusion-associated infections
    James J Goedert
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA
    Blood 100:1584-9. 2002
    ..04-fold (95% CI, 1.03-1.06) per year of age. Thus, HIV is associated with a markedly increased risk of HCV-related ESLD for persons with hemophilia, particularly with HBV infection, low CD4(+) lymphocytes, or older age...
  67. ncbi request reprint Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Tria
    Bruce Shiramizu
    University of Hawaii, Honolulu, Hawaii 96816, USA
    J Acquir Immune Defic Syndr 33:329-35. 2003
    ..A larger study is needed to demonstrate whether SPECT parameters alone or with other markers can provide information on fibrosis with the clinical significance obtained through liver biopsy...
  68. ncbi request reprint Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects
    Raymond T Chung
    Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    AIDS 16:1915-23. 2002
    ..We analysed changes in HCV RNA and the frequency of hepatotoxicity in co-infected patient enrolling in AIDS Clinical Trials Group trials, and determined whether HCV impairs successful immune reconstitution in these populations...
  69. ncbi request reprint Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
    Raymond T Chung
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 351:451-9. 2004
    ..We conducted a multicenter, randomized trial comparing peginterferon plus ribavirin with interferon plus ribavirin for the treatment of chronic hepatitis C in persons coinfected with HIV...
  70. ncbi request reprint GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype
    Carolynne Schwarze-Zander
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    J Infect Dis 194:410-9. 2006
    ..We therefore investigated (1) the prevalence and genotype of GBV-C in hepatitis C virus (HCV)/HIV-coinfected patients and (2) the impact of HCV treatment on GBV-C RNA clearance...
  71. ncbi request reprint Viral factors associated with cytokine expression during HCV/HIV co-infection
    Jason T Blackard
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Interferon Cytokine Res 27:263-9. 2007
    ..Further studies are warranted to identify noninvasive markers of liver disease for the clinical management of HCV disease, particularly when liver biopsies have not been performed or are contraindicated...
  72. ncbi request reprint Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection
    Camilla S Graham
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    AIDS 20:345-51. 2006
    ..To test the hypothesis that hepatitis C virus (HCV)-specific interferon (IFN)gamma immune responses are correlated with HCV virological response following treatment in subjects with HIV-1 and HCV co-infection...
  73. ncbi request reprint Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection
    Camilla S Graham
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    AIDS 19:767-73. 2005
    ..To test the hypothesis that antigen-specific interferon (IFN)gamma responses are correlated with milder liver disease in subjects coinfected with HIV-1 and hepatitis C virus (HCV)...
  74. ncbi request reprint CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV coinfection versus HCV monoinfection
    Nadia Alatrakchi
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 191:702-9. 2005
    ..We sought to determine whether T cell responses were present in the liver of patients with human immunodeficiency virus (HIV) and HCV coinfection...
  75. ncbi request reprint Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection
    Marshall J Glesby
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Infect Dis 191:686-93. 2005
    ..We explored the strategy of initial immunostimulatory therapy with interleukin (IL)-2, followed by the addition of specific anti-HCV therapy, as a possible synergistic approach to treatment...
  76. ncbi request reprint Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127
    Marion G Peters
    University of California, San Francisco, San Francisco, CA, USA
    Hepatology 44:1110-6. 2006
    ..In conclusion, over 48 weeks, treatment with either ADV or TDF resulted in clinically important suppression of serum HBV DNA. Both drugs are safe and efficacious for patients coinfected with HBV and HIV...
  77. pmc Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses
    Nadia Alatrakchi
    Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Boston, MA 02115, USA
    J Virol 81:5882-92. 2007
    ..In conclusion, blockade of TGF-beta secretion could enhance peripheral HCV-specific T-cell responses even in the presence of HIV coinfection...
  78. ncbi request reprint Effects of HCV treatment on cytokine expression during HCV/HIV coinfection
    Jason T Blackard
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Interferon Cytokine Res 26:834-8. 2006
    ....

Research Grants13

  1. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth Sherman; Fiscal Year: 2007
    ....
  2. Mentorship in Liver Disease
    Kenneth Sherman; Fiscal Year: 2007
    ..3. Review of the specific research activities funded by NIH and the pharmaceutical industry that serve as a structural framework for patient-oriented research ..
  3. Liver Disease and HIV
    Kenneth Sherman; Fiscal Year: 2006
    ..Particular attention will be played to development of new research concepts and establishment of collaborative associations. ..
  4. HCV Genomic Variability in HIV Infected Hemophiliacs
    Kenneth Sherman; Fiscal Year: 2004
    ..Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. ..
  5. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth E Sherman; Fiscal Year: 2010
    ....